Human Microbiome Market

The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.

An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.

Human Microbiome Market contains market size and forecasts of Human Microbiome in Global, including the following market information:

Global Human Microbiome Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Human Microbiome market was valued at 396 million in 2021 and is projected to reach US$ 1483.8 million by 2028, at a CAGR of 20.8% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Gastrointestinal Tract Human Micobiome Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Human Microbiome include Vedanta, Seres Therapeutics, Second Genome, Rebiotix, ActoGeniX, Enterome BioScience, AvidBiotics, 4D Pharma Research Ltd and Enterologics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Human Microbiome companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Human Microbiome Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Human Microbiome Market Segment Percentages, by Type, 2021 (%)

Gastrointestinal Tract Human Micobiome

Urogenital Tract Human Micobiome

Others

Global Human Microbiome Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Human Microbiome Market Segment Percentages, by Application, 2021 (%)

Treatment

Diagnosis

Global Human Microbiome Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Human Microbiome Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Human Microbiome revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Human Microbiome revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Vedanta

Seres Therapeutics

Second Genome

Rebiotix

ActoGeniX

Enterome BioScience

AvidBiotics

4D Pharma Research Ltd

Enterologics

Metabogen

Metabiomics

Ritter Pharmaceuticals

Osel

Symberix

Miomics

Symbiotix Biotherapies

MicroBiome Therapeutics LLC